Anna Schwendeman

Anna Schwendeman is a Professor of Pharmaceutical Sciences at the University of Michigan College of Pharmacy. Her research focuses on synthetic high-density lipoprotein (HDL) nanomedicines for treating atherosclerosis and other diseases through cholesterol transport and targeted delivery. She has extensive experience in pharmaceutical industry (Cerenis Therapeutics, Pfizer, Esperion Therapeutics) and has translated multiple HDL therapies to Phase II clinical trials.

Research Interests:

• Rational design of HDL nanomedicines
• Phospholipid composition optimization
• Apolipoprotein A-I mimic peptides
• Therapeutic applications for Alzheimer’s, sepsis, lupus, and diabetic nephropathy
• Targeted delivery to SR-BI-expressing tumors
• Regulatory science for complex parenteral products

Scientific Awards:

• American Heart Association Fellow (2023)
• Controlled Release Society Fellow (2023)
• American Heart Association Scientist Development Grant (2013)
• Presidential Fellowship, The Ohio State University (2000)
• Biomedical Innovation Shark Tank Winner (2015)

Grants & Collaborations: Research supported by the American Heart Association and U.S. Food and Drug Administration. Collaborative projects include HDL utility in Alzheimer’s disease, sepsis, and glioblastoma treatment. She also develops science-based regulations for testing nanoparticles and recombinant proteins.